Skip to main content
Login
Contact
Subscribe
Search form
Search
The Decatur Daily Democrat
Home
Forms
Delivery Concerns
News
Sports
Obituaries
Classifieds
Place an Ad
Classified Display Ads
Photos
Videos
Games
Entertainment
Local Guide
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Arena Pharmaceuticals
(NQ:
ARNA
)
71.46
USD
-2.11 (-2.87%)
Official Closing Price
Updated: 4:10 PM EST, Mar 8, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Arena Pharmaceuticals
< Previous
1
2
3
4
5
Next >
Arena Pharmaceuticals Reports Topline Results from Phase 2b CAPTIVATE Clinical Trial
March 02, 2021
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the randomized, double-blind, placebo-controlled Phase 2b CAPTIVATE clinical trial evaluating three doses of olorinab, a...
From
Business Wire News Releases
Arena Reports Fourth Quarter Financial Results with Strong Liquidity Position and Maintained Pipeline Progress Over the Quarter
February 23, 2021
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2020.
From
Business Wire News Releases
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 18, 2021
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on February 15, 2021, the Compensation Committee of its Board of Directors granted to eleven new employees inducement stock options to...
From
Business Wire News Releases
Arena Pharmaceuticals to Release Fourth Quarter & Full-Year 2020 Financial Results and Provide Corporate Update on February 23
February 16, 2021
Arena Pharmaceuticals to Release Fourth Quarter & Full-Year 2020 Financial Results and Provide Corporate Update on February 23.
From
Business Wire News Releases
Arena Pharmaceuticals Announces Changes to Board of Directors
February 16, 2021
Industry veteran Garry Neil, MD named Board Chair. Nawal Ouzren, CEO of Sensorion named to Board.
From
Business Wire News Releases
Arena Pharmaceuticals Completes Full Enrollment of Etrasimod Phase 3 ELEVATE UC 52 Trial
February 02, 2021
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has completed full enrollment of the Phase 3 ELEVATE UC 52 trial evaluating the safety and efficacy of etrasimod, a highly selective,...
From
Business Wire News Releases
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 22, 2021
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on January 15, 2021, the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to...
From
Business Wire News Releases
Arena Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 13
December 22, 2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, is scheduled to present virtually at the 39th Annual J.P. Morgan...
From
PR Newswire
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 18, 2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on December 15, 2020, the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to...
From
PR Newswire
Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference
December 11, 2020
- Data selected for late-breaker oral presentation on December 14
From
PR Newswire
Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod Phase 3 ELEVATE UC 52 Trial
December 08, 2020
- Evaluating 2 mg etrasimod in study participants with moderately to severely active ulcerative colitis (UC)
From
PR Newswire
Arena Pharmaceuticals Announces R&D Leadership Transition
November 30, 2020
Arena Pharmaceuticals announces the appointment of Paul D. Streck, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer.
From
Business Wire News Releases
Arena Pharmaceuticals to Present at the Evercore ISI HealthCONx Conference on December 1
November 24, 2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 3rd...
From
PR Newswire
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 19, 2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on November 15, 2020, the Compensation Committee of its Board of Directors granted to 13 new employees inducement stock options to...
From
PR Newswire
Arena Reports Third Quarter Financial Results with Strong Cash Position, Advancing Etrasimod Into a Phase 3 Registrational Program in Atopic Dermatitis
November 09, 2020
- Delivered compelling topline results from ADVISE Ph 2b trial evaluating etrasimod in atopic dermatitis; advancing into a Ph 3 registrational program
From
PR Newswire
Arena Pharmaceuticals Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis (AD), Reports Compelling Topline Results from Phase 2b ADVISE Trial
November 09, 2020
- Etrasimod 2 mg in the primary analysis achieved statistical significance of the registrational endpoint vIGA at week 12
From
PR Newswire
Arena Pharmaceuticals to Release Third Quarter 2020 Financial Results and Provide Corporate Update on November 9
November 02, 2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third quarter 2020 financial results and provide a corporate update on Monday, November 9, 2020, after the close of the U.S. financial...
From
PR Newswire
Arena Pharmaceuticals Announces Launch of Longboard Pharmaceuticals With $56M Financing, Building a Novel Neuroscience Drug Development Company
October 28, 2020
- Longboard Pharmaceuticals (formerly Arena Neuroscience) is an Arena-founded independent company focused on advancing promising investigational therapies for rare neurological diseases
From
PR Newswire
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 20, 2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on October 15, 2020, the Compensation Committee of its Board of Directors granted to seven new employees inducement stock options to...
From
PR Newswire
Arena Pharmaceuticals' Presence at United European Gastroenterology Week Strengthens Ongoing Commitment to the Gastrointestinal Disease Community
October 09, 2020
- New data from the Phase 2 OASIS trial and its open-label extension for etrasimod in ulcerative colitis
From
PR Newswire
Arena Pharmaceuticals Completes Full Enrollment of Olorinab Phase 2 CAPTIVATE Trial for Abdominal Pain in Irritable Bowel Syndrome
October 01, 2020
- Evaluating 3 doses of olorinab in study participants with the clinical diagnosis of irritable bowel syndrome with predominant constipation (IBS-C) or diarrhea (IBS-D)
From
PR Newswire
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 18, 2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on September 15, 2020, the Compensation Committee of its Board of Directors granted to nine new employees inducement stock options to...
From
PR Newswire
Arena Pharmaceuticals to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit
September 18, 2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the Jefferies Virtual Next...
From
PR Newswire
Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 12 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis
September 16, 2020
- Evaluating etrasimod 2 mg in patients with the clinical diagnosis of moderately to severely active ulcerative colitis (UC)
From
PR Newswire
Savvy Companies Eye Promising Potential in Multi-Billion-Dollar Industry
September 11, 2020
From
CannabisNewsWire
Savvy Companies Eye Promising Potential in Multi-Billion-Dollar Industry
September 11, 2020
From
InvestorBrandNetwork
Savvy Companies Eye Promising Potential in Multi-Billion-Dollar Industry
September 11, 2020
CannabisNewsWire Editorial Coverage
From
PR Newswire
Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
September 03, 2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that that members of its senior management team will participate in the upcoming investor conferences:
From
PR Newswire
Arena Pharmaceuticals Announces First Subject Dosed in Phase 2 Trial Evaluating Etrasimod in Alopecia Areata
September 01, 2020
- Evaluating etrasimod 2 mg in patients with the clinical diagnosis of moderate-to-severe alopecia areata
From
PR Newswire
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 19, 2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on August 15, 2020, the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to...
From
PR Newswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.